A Study to Evaluate the Efficacy and Safety of Novel Treatment Combinations in Participants With Ovarian Cancer

NCT03574779 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

77

Enrollment

INDUSTRY

Sponsor class

Conditions

Ovarian Neoplasms

Interventions

DRUG: Niraparib
BIOLOGICAL: TSR-042
BIOLOGICAL: Bevacizumab
DRUG: Carboplatin
DRUG: Paclitaxel

Sponsor

Tesaro, Inc.